OncoMatch/Clinical Trials/NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery
Is NCT07762924 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Endocrine Therapy (Optional) for ductal carcinoma in situ, dcis.
Treatment: Endocrine Therapy (Optional) — This is a single-center, prospective phase II clinical study designed to evaluate whether omission of postoperative radiotherapy is clinically acceptable in young patients with low-risk ductal carcinoma in situ (DCIS) following breast-conserving surgery. Eligible patients include women younger than 40 years with low- or intermediate-grade DCIS, tumor size ≤1 cm, negative surgical margins ≥3 mm, absence of comedo necrosis, and unifocal screen-detected disease. Patients in the radiotherapy omission cohort will undergo close surveillance after surgery, with endocrine therapy permitted according to physician discretion. The primary endpoint is 5-year ipsilateral breast tumor recurrence (IBTR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Excluded: TP53 germline mutation
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07762924 currently recruiting?
Yes, this trial is currently recruiting patients.
Are patients with BRCA1 alterations eligible?
No. BRCA1 germline mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 germline mutation is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 40 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify